Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
Yusuke SakaguchiTakayuki HamanoAtsushi WadaIkuto MasakanePublished in: Journal of the American Society of Nephrology : JASN (2019)
Among patients undergoing hemodialysis, use of long-acting ESAs might be associated with a higher risk of death than use of short-acting ESAs.